Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Emerson Electric Co. (EMR) vs Illumina, Inc. (ILMN) Price & Performance

Emerson Electric Co.Trade
Illumina, Inc.Trade

Price performance (Past 24H)

Key statistics

Emerson Electric Co. vs Illumina, Inc. — how do they compare? Emerson Electric Co. trades at $137.27 (market cap $76.31B), while Illumina, Inc. trades at $189.47 (market cap $28.32B). The key difference: Emerson Electric Co. is far larger — about 2.7× Illumina, Inc.'s market cap, and Emerson Electric Co. pays a 1.63% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.

EMRILMN
Market Cap
$76.31B$28.32B
Sector
IndustrialsHealth
52-Week High
$161.69$194.33
52-Week Low
$123.30$91.00
Enterprise Value
$88.58B$29.70B
Dividend Yield
1.63%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Emerson Electric Co.

Emerson Electric (EMR) trades at $137.06, up 0.7% on the day, with a bearish technical signal but strong analyst support. Recent earnings have mostly beaten expectations, with Q2 2026 results pending. The company maintains solid profitability with a 13.35% net income margin and a consensus price target of $157.60, suggesting 15% upside. Cash flow trends show operational strength despite net outflows, and a dividend of $0.56 was recently declared.

EMR presents a mixed outlook: bullish fundamentals and analyst ratings contrast with near-term technical weakness. Investment appeal hinges on earnings execution and sector momentum, while risks include debt levels and market volatility. The stock's valuation at a P/E of 31.54 requires sustained growth to justify further gains.

Illumina, Inc.

Illumina (ILMN) trades at $188.27, down 1.53% on the day, yet maintains a strong technical and fundamental posture. The stock is in a bullish trend, supported by consistent earnings beats, robust profitability margins, and positive analyst sentiment. Recent news highlights strong momentum in 2026, driven by sequencing demand and new product launches, positioning the company for growth despite competitive pressures.

The outlook for ILMN is positive, with earnings growth and market leadership in genomics offering upside potential. Key risks include intensifying competition from new entrants like Roche and execution challenges in a dynamic healthcare landscape. Investor sentiment remains buoyant, but vigilance on competitive threats and margin sustainability is warranted for sustained performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Emerson Electric Co.

Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.

Read more on EMR

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Read more on ILMN